Ibrutinib-rituximab therapy is superior to gold standard therapy for CLL
According to a latest report, ibrutinib-rituximab (IR) therapy offers superior progression free survival (PFS) than fludarabine, cyclophosphamide, and rituximab (FCR) in patients with immunoglobulin heavy chain variable region (IGHV) gene mutated or unmutated chronic lymphocytic leukemia (CLL). This was an updated report from the E1912 trial published in the journal, Blood (American Society of Hematology). […]
Ibrutinib-rituximab therapy is superior to gold standard therapy for CLL Read More »









